13/02/26 -"What is Novo really up against?"
13/02/26 -"What is Novo really up against?"
Despite being one of the only two players in the obesity market currently, Novo Nordisk has been struggling to eke out growth, whereas Eli Lilly has continued to grow largely unabated. Let’s try and assess the factors that might be dragging Novo down. Is geopolitics one among the culprits behind Novo’s misery?
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
| Corporate broking | NO |
| Trading in corporate shares | NO |
| Analyst ownership | NO |
| Advising of corporate (strategy, marketing, debt, etc) | NO |
| Research paid for by corporate | NO |
| Provision of corporate access paid for by corporate | NO |
| Link between and a banking entity | NO |
| Brokerage activity at AlphaValue | NO |